Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Budesonide/Formoterol vs Symbicort in Adult Asthma
NCT05322707Phase 3Completed
- Sponsor
- Cipla
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of budesonide + formoterol in asthma (3 arms), sponsored by Cipla. Primary endpoints: Area under the serial Force Expiration volume1 and Change in FEV1 from baseline at 6 weeks. Started Apr 2022; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05322707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322707.